Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing three active pharmaceutical ingredients: - **Aspirin** is an acetylsalicylic acid, a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX)-1 and COX-2 enzymes, reducing prostaglandin synthesis. It is used for its analgesic, antipyretic, anti-inflammatory, and antiplatelet effects. - **Diclofenac** is a phenylacetic acid derivative NSAID that inhibits COX-1 and COX-2 enzymes to reduce inflammation and pain. It is commonly used to treat osteoarthritis and rheumatoid arthritis[2]. - **Metformin** is a biguanide antihyperglycemic agent primarily used in the management of type 2 diabetes mellitus. It decreases hepatic glucose production, increases insulin sensitivity, and enhances peripheral glucose uptake[1]. There are no known approved or marketed products combining all three agents together as a single formulation. Each component has distinct mechanisms of action targeting different pathways—aspirin and diclofenac both act on prostaglandin synthesis but have different pharmacokinetics; metformin acts on metabolic pathways related to glucose homeostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + diclofenac + metformin.